메뉴 건너뛰기




Volumn 9, Issue 3, 2014, Pages

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen

(14)  Cavaco Silva, Joana a   Abecasis, Ana a   Miranda, Ana Cláudia b   Poças, José c   Narciso, Jorge d   Águas, Maria João e   Maltez, Fernando f   Almeida, Isabel g   Germano, Isabel f   Diniz, António h   Gonçalves, Maria De Fátima b   Gomes, Perpétua a,b,i   Cunha, Celso a   Camacho, Ricardo Jorge a,j  


Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; INTEGRASE INHIBITOR; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 84899857420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092747     Document Type: Article
Times cited : (21)

References (75)
  • 1
    • 33748452016 scopus 로고    scopus 로고
    • Available: Accessed 18 November 2013
    • UNAIDS (2006) AIDS epidemic update: December 2006. Available: http://data.unaids.org/pub/epireport/2006/2006-epiupdate-en.pdf. Accessed 18 November 2013.
    • (2006) AIDS Epidemic Update: December 2006
  • 2
    • 84899815351 scopus 로고    scopus 로고
    • Unidade de Referência e Vigilância Laboratorial Epidemiológica. Núcleo de Vigilância Laboratorial de Doenças Infecciosas Documento SIDA 144. Available: Accessed 18 November 2013
    • Departamento de Doenças Infecciosas do INSA. Unidade de Referência e Vigilância Laboratorial Epidemiológica. Núcleo de Vigilância Laboratorial de Doenças Infecciosas (2013) Infeção VIH/SIDA: a situação em Portugal a 31 de Dezembro de 2012. Documento SIDA 144. Available: http://repositorio.insa.pt/ bitstream/10400.18/1622/3/Relatorio-SIDA-2012-WEB.pdf. Accessed 18 November 2013.
    • (2013) Infeção VIH/SIDA: A Situação Em Portugal a 31 de Dezembro de 2012
  • 6
    • 1542319002 scopus 로고    scopus 로고
    • Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis
    • Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, et al. (2004) Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 9: 57-65. (Pubitemid 38313948)
    • (2004) Antiviral Therapy , vol.9 , Issue.1 , pp. 57-65
    • Witvrouw, M.1    Pannecouque, C.2    Switzer, W.M.3    Folks, T.M.4    De Clercq, E.5    Heneine, W.6
  • 7
    • 1842502574 scopus 로고    scopus 로고
    • Are fusion inhibitors active against all HIV variants?
    • DOI 10.1089/088922204322996590
    • Poveda E, Rodes B, Toro C, Soriano V (2004) Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 20: 347-348. (Pubitemid 38429408)
    • (2004) AIDS Research and Human Retroviruses , vol.20 , Issue.3 , pp. 347-348
    • Poveda, E.1    Rodes, B.2    Toro, C.3    Soriano, V.4
  • 10
    • 33645121140 scopus 로고    scopus 로고
    • Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy
    • Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, et al. (2006) Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother 57: 709-713.
    • (2006) J Antimicrob Chemother , vol.57 , pp. 709-713
    • Rodes, B.1    Sheldon, J.2    Toro, C.3    Jimenez, V.4    Alvarez, M.A.5
  • 11
    • 65649146417 scopus 로고    scopus 로고
    • Antiretroviral drug resistance in HIV-2: Three amino acid changes are sufficient for classwide nucleoside analogue resistance
    • Smith RA, Anderson DJ, Pyrak CL, Preston BD, Gottlieb GS (2009) Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance. J Infect Dis 199: 1323-1326.
    • (2009) J Infect Dis , vol.199 , pp. 1323-1326
    • Smith, R.A.1    Anderson, D.J.2    Pyrak, C.L.3    Preston, B.D.4    Gottlieb, G.S.5
  • 12
    • 33846648687 scopus 로고    scopus 로고
    • Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors
    • DOI 10.1128/AAC.00870-06
    • Ntemgwa M, Brenner BG, Oliveira M, Moisi D, Wainberg MA (2007) Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother 51: 604-610. (Pubitemid 46185279)
    • (2007) Antimicrobial Agents and Chemotherapy , vol.51 , Issue.2 , pp. 604-610
    • Ntemgwa, M.1    Brenner, B.G.2    Oliveira, M.3    Moisi, D.4    Wainberg, M.A.5
  • 13
    • 29144436631 scopus 로고    scopus 로고
    • High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART
    • Rodes B, Toro C, Sheldon JA, Jimenez V, Mansinho K, et al. (2006) High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 20: 127-129. (Pubitemid 41818127)
    • (2006) AIDS , vol.20 , Issue.1 , pp. 127-129
    • Rodes, B.1    Toro, C.2    Sheldon, J.A.3    Jimenez, V.4    Mansinho, K.5    Soriano, V.6
  • 14
    • 0030614408 scopus 로고    scopus 로고
    • 2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro
    • DOI 10.1021/bi961849o
    • Lee SP, Xiao J, Knutson JR, Lewis MS, Han MK (1997) Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry 36: 173-180. (Pubitemid 27024690)
    • (1997) Biochemistry , vol.36 , Issue.1 , pp. 173-180
    • Lee, S.P.1    Xiao, J.2    Knutson, J.R.3    Lewis, M.S.4    Han, M.K.5
  • 16
    • 0026740842 scopus 로고
    • Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro
    • Drelich M, Wilhelm R, Mous J (1992) Identification of amino acid residues critical for endonuclease and integration activities of HIV-1 IN protein in vitro. Virology 188: 459-468.
    • (1992) Virology , vol.188 , pp. 459-468
    • Drelich, M.1    Wilhelm, R.2    Mous, J.3
  • 17
    • 0026649557 scopus 로고
    • Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro
    • Engelman A, Craigie R (1992) Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol 66: 6361-6369.
    • (1992) J Virol , vol.66 , pp. 6361-6369
    • Engelman, A.1    Craigie, R.2
  • 18
    • 0026719238 scopus 로고
    • Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases
    • Kulkosky J, Jones KS, Katz RA, Mack JP, Skalka AM (1992) Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol 12: 2331-2338.
    • (1992) Mol Cell Biol , vol.12 , pp. 2331-2338
    • Kulkosky, J.1    Jones, K.S.2    Katz, R.A.3    Mack, J.P.4    Skalka, A.M.5
  • 20
    • 0032189652 scopus 로고    scopus 로고
    • Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction
    • DOI 10.1093/emboj/17.19.5832
    • Esposito D, Craigie R (1998) Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J 17: 5832-5843. (Pubitemid 28445994)
    • (1998) EMBO Journal , vol.17 , Issue.19 , pp. 5832-5843
    • Esposito, D.1    Craigie, R.2
  • 21
    • 0030764902 scopus 로고    scopus 로고
    • The core domain of HIV-1 integrase recognizes key features of its DNA substrates
    • DOI 10.1074/jbc.272.41.25809
    • Gerton JL, Brown PO (1997) The core domain of HIV-1 integrase recognizes key features of its DNA substrates. J Biol Chem 272: 25809-25815. (Pubitemid 27438903)
    • (1997) Journal of Biological Chemistry , vol.272 , Issue.41 , pp. 25809-25815
    • Gerton, J.L.1    Brown, P.O.2
  • 22
    • 0030828521 scopus 로고    scopus 로고
    • Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking
    • Jenkins TM, Esposito D, Engelman A, Craigie R (1997) Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking. EMBO J 16: 6849-6859. (Pubitemid 27503496)
    • (1997) EMBO Journal , vol.16 , Issue.22 , pp. 6849-6859
    • Jenkins, T.M.1    Esposito, D.2    Engelman, A.3    Craigie, R.4
  • 23
    • 0035824646 scopus 로고    scopus 로고
    • Role of the nonspecific DNAbinding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration
    • Appa RS, Shin CG, Lee P, Chow SA (2001) Role of the nonspecific DNAbinding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration. J Biol Chem 276: 45848-45855.
    • (2001) J Biol Chem , vol.276 , pp. 45848-45855
    • Appa, R.S.1    Shin, C.G.2    Lee, P.3    Chow, S.A.4
  • 24
    • 0034908087 scopus 로고    scopus 로고
    • Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection
    • DOI 10.1128/JVI.75.16.7756-7762.2001
    • Harper AL, Skinner LM, Sudol M, Katzman M (2001) Use of patient-derived human immunodeficiency virus type 1 integrases to identify a protein residue that affects target site selection. J Virol 75: 7756-7762. (Pubitemid 32738037)
    • (2001) Journal of Virology , vol.75 , Issue.16 , pp. 7756-7762
    • Harper, A.L.1    Skinner, L.M.2    Sudol, M.3    Katzman, M.4
  • 25
    • 0032601402 scopus 로고    scopus 로고
    • HIV integrase structure and function
    • Esposito D, Craigie R (1999) HIV integrase structure and function. Adv Virus Res 52: 319-333.
    • (1999) Adv Virus Res , vol.52 , pp. 319-333
    • Esposito, D.1    Craigie, R.2
  • 26
    • 0035796559 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 integrase: Arrangement of protein domains in active cDNA complexes
    • DOI 10.1093/emboj/20.13.3565
    • Gao K, Butler SL, Bushman F (2001) Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes. EMBO J 20: 3565-3576. (Pubitemid 32634363)
    • (2001) EMBO Journal , vol.20 , Issue.13 , pp. 3565-3576
    • Gao, K.1    Butler, S.L.2    Bushman, F.3
  • 27
    • 0028067324 scopus 로고
    • The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding
    • Engelman A, Hickman AB, Craigie R (1994) The core and carboxyl-terminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol 68: 5911-5917. (Pubitemid 24258608)
    • (1994) Journal of Virology , vol.68 , Issue.9 , pp. 5911-5917
    • Engelman, A.1    Hickman, A.B.2    Craigie, R.3
  • 28
    • 0027210608 scopus 로고
    • Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type 1 integrase protein
    • Vink C, Oude Groeneger AM, Plasterk RH (1993) Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res 21: 1419-1425. (Pubitemid 23154373)
    • (1993) Nucleic Acids Research , vol.21 , Issue.6 , pp. 1419-1425
    • Vink, C.1    Groeneger, A.A.M.O.2    Plasterk, R.H.A.3
  • 29
    • 0027205243 scopus 로고
    • Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis
    • Woerner AM, Marcus-Sekura CJ (1993) Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Res 21: 3507-3511. (Pubitemid 23241486)
    • (1993) Nucleic Acids Research , vol.21 , Issue.15 , pp. 3507-3511
    • Woerner, A.M.1    Marcus-Sekura, C.J.2
  • 30
    • 0029980485 scopus 로고    scopus 로고
    • A soluble active mutant of HIV-1 integrase: Involvement of both the core and carboxyl-terminal domains in multimerization
    • Jenkins TM, Engelman A, Ghirlando R, Craigie R (1996) A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 271: 7712-7718.
    • (1996) J Biol Chem , vol.271 , pp. 7712-7718
    • Jenkins, T.M.1    Engelman, A.2    Ghirlando, R.3    Craigie, R.4
  • 31
    • 48749125376 scopus 로고    scopus 로고
    • Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatmentexperienced HIV type 2 patients
    • Xu L, Anderson J, Ferns B, Cook P, Wildfire A, et al. (2008) Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatmentexperienced HIV type 2 patients. AIDS Res Hum Retroviruses 24: 1003-1007.
    • (2008) AIDS Res Hum Retroviruses , vol.24 , pp. 1003-1007
    • Xu, L.1    Anderson, J.2    Ferns, B.3    Cook, P.4    Wildfire, A.5
  • 32
    • 80855139558 scopus 로고    scopus 로고
    • Phenotypic Susceptibility of HIV-2 to Raltegravir: Integrase Mutations Q148R and N155H Confer Raltegravir Resistance
    • Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, et al. (2011) Phenotypic Susceptibility of HIV-2 to Raltegravir: Integrase Mutations Q148R and N155H Confer Raltegravir Resistance. AIDS 25: 2235-2241.
    • (2011) AIDS , vol.25 , pp. 2235-2241
    • Smith, R.A.1    Raugi, D.N.2    Kiviat, N.B.3    Hawes, S.E.4    Mullins, J.I.5
  • 33
    • 54549099338 scopus 로고    scopus 로고
    • HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    • Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, et al. (2008) HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 62: 914-920.
    • (2008) J Antimicrob Chemother , vol.62 , pp. 914-920
    • Roquebert, B.1    Damond, F.2    Collin, G.3    Matheron, S.4    Peytavin, G.5
  • 35
    • 34447263572 scopus 로고    scopus 로고
    • Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance
    • Lataillade M, Chiarella J, Kozal MJ (2007) Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12: 563-570. (Pubitemid 47041156)
    • (2007) Antiviral Therapy , vol.12 , Issue.4 , pp. 563-570
    • Lataillade, M.1    Chiarella, J.2    Kozal, M.J.3
  • 37
    • 78349311194 scopus 로고    scopus 로고
    • Invitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572
    • Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, et al. (2010) Invitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 24: 2753-2755.
    • (2010) AIDS , vol.24 , pp. 2753-2755
    • Charpentier, C.1    Larrouy, L.2    Collin, G.3    Damond, F.4    Matheron, S.5
  • 38
    • 77951298322 scopus 로고    scopus 로고
    • Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc
    • Armstrong-James D, Stebbing J, Scourfield A, Smit E, Ferns B, et al. (2010) Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 86: 224-226.
    • (2010) Antiviral Res , vol.86 , pp. 224-226
    • Armstrong-James, D.1    Stebbing, J.2    Scourfield, A.3    Smit, E.4    Ferns, B.5
  • 39
    • 44449096529 scopus 로고    scopus 로고
    • Raltegravir treatment response in an HIV-2 infected patient: A case report
    • DOI 10.1097/QAD.0b013e3282f9b165, PII 0000203020080531000014
    • Garrett N, Xu L, Smit E, Ferns B, El Gadi S, et al. (2008) Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 22: 1091-1092. (Pubitemid 351769751)
    • (2008) AIDS , vol.22 , Issue.9 , pp. 1091-1092
    • Garrett, N.1    Xu, L.2    Smit, E.3    Ferns, B.4    El-Gadi, S.5    Anderson, J.6
  • 40
    • 80855139786 scopus 로고    scopus 로고
    • Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient
    • Wandeler G, Furrer H, Rauch A (2011) Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. AIDS 25: 2306-2308.
    • (2011) AIDS , vol.25 , pp. 2306-2308
    • Wandeler, G.1    Furrer, H.2    Rauch, A.3
  • 42
    • 80051782593 scopus 로고    scopus 로고
    • G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
    • Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, et al. (2011) G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not. Retrovirology 8: 68.
    • (2011) Retrovirology , vol.8 , pp. 68
    • Ni, X.J.1    Delelis, O.2    Charpentier, C.3    Storto, A.4    Collin, G.5
  • 43
    • 53549113615 scopus 로고    scopus 로고
    • Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen
    • Roquebert B, Blum L, Collin G, Damond F, Peytavin G, et al. (2008) Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 22: 2045-2046.
    • (2008) AIDS , vol.22 , pp. 2045-2046
    • Roquebert, B.1    Blum, L.2    Collin, G.3    Damond, F.4    Peytavin, G.5
  • 44
    • 69449092080 scopus 로고    scopus 로고
    • Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity
    • Salgado M, Toro C, Simon A, Garrido C, Blanco F, et al. (2009) Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. J Clin Virol 46: 173-175.
    • (2009) J Clin Virol , vol.46 , pp. 173-175
    • Salgado, M.1    Toro, C.2    Simon, A.3    Garrido, C.4    Blanco, F.5
  • 46
    • 70349221276 scopus 로고    scopus 로고
    • Dynamics of raltegravir resistance profile in an HIV type 2-infected patient
    • Xu L, Anderson J, Garrett N, Ferns B, Wildfire A, et al. (2009) Dynamics of raltegravir resistance profile in an HIV type 2-infected patient. AIDS Res Hum Retroviruses 25: 843-847.
    • (2009) AIDS Res Hum Retroviruses , vol.25 , pp. 843-847
    • Xu, L.1    Anderson, J.2    Garrett, N.3    Ferns, B.4    Wildfire, A.5
  • 47
    • 33645024195 scopus 로고    scopus 로고
    • CD4 cell recovery in treated HIV-2-infected adults is lower than expected: Results from the French ANRS CO5 HIV-2 cohort
    • Matheron S, Damond F, Benard A, Taieb A, Campa P, et al. (2006) CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS 20: 459-462.
    • (2006) AIDS , vol.20 , pp. 459-462
    • Matheron, S.1    Damond, F.2    Benard, A.3    Taieb, A.4    Campa, P.5
  • 48
    • 84866521761 scopus 로고    scopus 로고
    • Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: Implications for emerging HIV-2 treatment regimens
    • Smith RA, Raugi DN, Pan C, Coyne M, Hernandez A, et al. (2012) Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. PLoS One 7: e45372.
    • (2012) PLoS One , vol.7
    • Smith, R.A.1    Raugi, D.N.2    Pan, C.3    Coyne, M.4    Hernandez, A.5
  • 49
    • 40549125135 scopus 로고    scopus 로고
    • Resistance and cross-resistance to first generation integrase inhibitors: Insights from a Phase II study of elvitegravir (GS-9137)
    • McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, et al. (2007) Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir Ther 12:S11.
    • (2007) Antivir Ther , vol.12
    • McColl, D.J.1    Fransen, S.2    Gupta, S.3    Parkin, N.4    Margot, N.5
  • 50
    • 84877843704 scopus 로고    scopus 로고
    • Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness
    • Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, et al. (2013) Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother 57: 2654-2663.
    • (2013) Antimicrob Agents Chemother , vol.57 , pp. 2654-2663
    • Abram, M.E.1    Hluhanich, R.M.2    Goodman, D.D.3    Andreatta, K.N.4    Margot, N.A.5
  • 51
    • 84885769347 scopus 로고    scopus 로고
    • Dolutegravir interactions with HIV-1 integrase-DNA: Structural rationale for drug resistance and dissociation kinetics
    • DeAnda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, et al. (2013) Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One 8: e77448.
    • (2013) PLoS One , vol.8
    • DeAnda, F.1    Hightower, K.E.2    Nolte, R.T.3    Hattori, K.4    Yoshinaga, T.5
  • 52
    • 84873633830 scopus 로고    scopus 로고
    • Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravirresistant HIV type 1 infection: 24-Week results of the VIKING Study
    • Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, et al. (2013) Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravirresistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 207: 740-748.
    • (2013) J Infect Dis , vol.207 , pp. 740-748
    • Eron, J.J.1    Clotet, B.2    Durant, J.3    Katlama, C.4    Kumar, P.5
  • 54
    • 84874039772 scopus 로고    scopus 로고
    • Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
    • Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, et al. (2013) Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22.
    • (2013) Retrovirology , vol.10 , pp. 22
    • Mesplede, T.1    Quashie, P.K.2    Osman, N.3    Han, Y.4    Singhroy, D.N.5
  • 55
    • 84863393356 scopus 로고    scopus 로고
    • Characterization of the R263K mutation in HIV-1 integrase that confers lowlevel resistance to the second-generation integrase strand transfer inhibitor dolutegravir
    • Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, et al. (2012) Characterization of the R263K mutation in HIV-1 integrase that confers lowlevel resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86: 2696-2705.
    • (2012) J Virol , vol.86 , pp. 2696-2705
    • Quashie, P.K.1    Mesplede, T.2    Han, Y.S.3    Oliveira, M.4    Singhroy, D.N.5
  • 56
    • 1242269308 scopus 로고    scopus 로고
    • Polymorphism and Drug-Selected Mutations in the Protease Gene of Human Immunodeficiency Virus Type 2 from Patients Living in Southern France
    • DOI 10.1128/JCM.42.2.570-577.2004
    • Colson P, Henry M, Tourres C, Lozachmeur D, Gallais H, et al. (2004) Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol 42: 570-577. (Pubitemid 38222630)
    • (2004) Journal of Clinical Microbiology , vol.42 , Issue.2 , pp. 570-577
    • Colson, P.1    Henry, M.2    Tourres, C.3    Lozachmeur, D.4    Gallais, H.5    Gastaut, J.A.6    Moreau, J.7    Tamalet, C.8
  • 59
    • 3042666256 scopus 로고    scopus 로고
    • MUSCLE: Multiple sequence alignment with high accuracy and high throughput
    • Edgar RC (2004) MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32: 1792-1797.
    • (2004) Nucleic Acids Res , vol.32 , pp. 1792-1797
    • Edgar, R.C.1
  • 61
    • 84870441827 scopus 로고    scopus 로고
    • Website. Available: Accessed 18 November 2013
    • Guido van Rossum (2011) Python Language Website. Available: http://www.python.org/. Accessed 18 November 2013.
    • (2011) Python Language
    • Van Rossum, G.1
  • 63
    • 77957875432 scopus 로고    scopus 로고
    • Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
    • Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, et al. (2010) Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 65: 2305-2318.
    • (2010) J Antimicrob Chemother , vol.65 , pp. 2305-2318
    • Ceccherini-Silberstein, F.1    Malet, I.2    Fabeni, L.3    Dimonte, S.4    Svicher, V.5
  • 64
    • 0026668776 scopus 로고
    • Mutational analysis of the integrase protein of human immunodeficiency virus type 2
    • van Gent DC, Groeneger AA, Plasterk RH (1992) Mutational analysis of the integrase protein of human immunodeficiency virus type 2. Proc Natl Acad Sci U S A 89: 9598-9602.
    • (1992) Proc Natl Acad Sci U S A , vol.89 , pp. 9598-9602
    • Van Gent, D.C.1    Groeneger, A.A.2    Plasterk, R.H.3
  • 66
    • 70450273192 scopus 로고    scopus 로고
    • Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase
    • Dar MJ, Monel B, Krishnan L, Shun MC, Di Nunzio F, et al. (2009) Biochemical and virological analysis of the 18-residue C-terminal tail of HIV-1 integrase. Retrovirology 6: 94.
    • (2009) Retrovirology , vol.6 , pp. 94
    • Dar, M.J.1    Monel, B.2    Krishnan, L.3    Shun, M.C.4    Di Nunzio, F.5
  • 67
    • 79960219397 scopus 로고    scopus 로고
    • HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa
    • Gottlieb GS, Smith RA, Dia Badiane NM, Ba S, Hawes SE, et al. (2011) HIV-2 integrase variation in integrase inhibitor-naive adults in Senegal, West Africa. PLoS One 6: e22204.
    • (2011) PLoS One , vol.6
    • Gottlieb, G.S.1    Smith, R.A.2    Dia Badiane, N.M.3    Ba, S.4    Hawes, S.E.5
  • 68
    • 70349320511 scopus 로고    scopus 로고
    • Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors
    • Low A, Prada N, Topper M, Vaida F, Castor D, et al. (2009) Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 53: 4275-4282.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 4275-4282
    • Low, A.1    Prada, N.2    Topper, M.3    Vaida, F.4    Castor, D.5
  • 69
    • 73649137500 scopus 로고    scopus 로고
    • The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates
    • Buzon MJ, Dalmau J, Puertas MC, Puig J, Clotet B, et al. (2010) The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. AIDS 24: 17-25.
    • (2010) AIDS , vol.24 , pp. 17-25
    • Buzon, M.J.1    Dalmau, J.2    Puertas, M.C.3    Puig, J.4    Clotet, B.5
  • 70
    • 56749178876 scopus 로고    scopus 로고
    • Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on longterm antiretroviral therapy
    • Buzon MJ, Marfil S, Puertas MC, Garcia E, Clotet B, et al. (2008) Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on longterm antiretroviral therapy. Antivir Ther 13: 881-893.
    • (2008) Antivir Ther , vol.13 , pp. 881-893
    • Buzon, M.J.1    Marfil, S.2    Puertas, M.C.3    Garcia, E.4    Clotet, B.5
  • 71
    • 77957310350 scopus 로고    scopus 로고
    • Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness
    • Hu Z, Kuritzkes DR (2010) Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 55: 148-155.
    • (2010) J Acquir Immune Defic Syndr , vol.55 , pp. 148-155
    • Hu, Z.1    Kuritzkes, D.R.2
  • 72
    • 70349337790 scopus 로고    scopus 로고
    • Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure
    • Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, et al. (2009) Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 53: 4522-4524.
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 4522-4524
    • Fransen, S.1    Karmochkine, M.2    Huang, W.3    Weiss, L.4    Petropoulos, C.J.5
  • 73
    • 62549166235 scopus 로고    scopus 로고
    • Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients
    • Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, et al. (2009) Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63: 795-804.
    • (2009) J Antimicrob Chemother , vol.63 , pp. 795-804
    • Malet, I.1    Delelis, O.2    Soulie, C.3    Wirden, M.4    Tchertanov, L.5
  • 74
    • 80052668107 scopus 로고    scopus 로고
    • Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal
    • Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, et al. (2011) Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther 16: 937-940.
    • (2011) Antivir Ther , vol.16 , pp. 937-940
    • Charpentier, C.1    Larrouy, L.2    Matheron, S.3    Damond, F.4    Delelis, O.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.